To see all protocols that comply with the WHO Essential Medicine List 

The protocol this document is linked to, has been superseded as a superior alternative is available for use in clinical practice. ID 3726 Burkitt lymphoma dose modified R-CODOX-M is the more commonly used regimen.

This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document. 

Additional intrathecal therapy

High risk patients with proven CNS disease are to receive additional CNS directed therapy with intrathecal cytarabine and methotrexate with the FIRST cycle of dm CODOX-M only.r

Drug Dose Route Day Cycle
Cytarabine 70 mg Intrathecal 5 FIRST cycle of dm CODOX-M only
Methotrexate 12 mg Intrathecal 17
Calcium folinate (leucovorin) 15 mg PO 18

Note: This is in addition to intrathecal treatment given on Day 1, 3 and 15 as part of the dm CODOX-M protocol.

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Last reviewed:
Review due:
Superseded:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3215

29 Mar 2024